Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective
Journal of Inherited Metabolic Disease · 2024
DOI: 10.1002/jimd.12657 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2024. Verfasst von Tessa M A Peters und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Amino Acid Metabolism, Inborn Errors, Metabolomics, Succinate-Semialdehyde Dehydrogenase. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Stofwisselkracht, NIH/NICHD, SSADH Association (https://www.ssadh.net/).
Abstract (Originalsprache)
Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a rare neurometabolic disorder caused by disruption of the gamma‐aminobutyric acid (GABA) pathway. A more detailed understanding of its pathophysiology, beyond the accumulation of GABA and gamma‐hydroxybutyric acid (GHB), will increase our understanding of the disease and may support novel therapy development. To this end, we compared biochemical body fluid profiles from SSADHD patients with controls using next‐generation metabolic screening (NGMS). Targeted analysis of NGMS data from cerebrospinal fluid (CSF) showed a moderate increase of aspartic acid, glutaric acid, glycolic acid, 4‐guanidinobutanoic acid, and 2‐hydroxyglutaric acid, and prominent elevations of GHB and 4,5‐dihydroxyhexanoic acid (4,5‐DHHA) in SSADHD samples. Remarkably, the intensities of 4,5‐DHHA and GHB showed a significant positive correlation in control CSF, but not in patient CSF. In an established zebrafish epilepsy model, 4,5‐DHHA showed increased mobility that may reflect limited epileptogenesis. Using untargeted metabolomics, we identified 12 features in CSF with high biomarker potential. These had comparable increased fold changes as GHB and 4,5‐DHHA. For 10 of these features, a similar increase was found in plasma, urine and/or mouse brain tissue for SSADHD compared to controls. One of these was identified as the novel biomarker 4,5‐dihydroxyheptanoic acid. The intensities of selected features in plasma and urine of SSADHD patients positively correlated with the clinical severity score of epilepsy and psychiatric symptoms of those patients, and also showed a high mutual correlation. Our findings provide new insights into the (neuro)metabolic disturbances in SSADHD and give leads for further research concerning SSADHD pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Laboratory Medicine, Translational Metabolic Laboratory (TML), Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.
- Department of Otorhinolaryngology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Clinical Chemistry, Metabolic Unit, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.
- Clinical Biochemistry Department, Institut de Recerca Sant Joan de Déu, CIBERER and MetabERN Hospital Sant Joan de Déu, Barcelona, Spain.
ORCID-Profile: Tessa M A Peters, Udo F H Engelke, Jean-Baptiste Roullet, Erik de Vrieze, Erwin van Wijk, Mirjam M C Wamelink, Rafael Artuch, Ivo Barić, Jona Merx, Thomas J Boltje, Jonathan Martens, Michèl A A P Willemsen, Marcel M Verbeek, Ron A Wevers, K Michael Gibson, Karlien L M Coene
Förderung
- Stichting Stofwisselkracht
- NIH/NICHD
- SSADH Association (https://www.ssadh.net/)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Peters, T. M. A., Engelke, U. F. H., de Boer, S., Reintjes, J. T. G., Roullet, J. B., Broekman, S., de Vrieze, E., van Wijk, E., Wamelink, M. M. C., Artuch, R., Barić, I., Merx, J., Boltje, T. J., Martens, J., Willemsen, M. A. A. P., Verbeek, M. M., Wevers, R. A., Gibson, K. M., & Coene, K. L. M. (2024). Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12657
Vancouver
Peters TMA, Engelke UFH, de Boer S, Reintjes JTG, Roullet JB, Broekman S, et al. Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective. Journal of Inherited Metabolic Disease. 2024. doi:10.1002/jimd.12657
BibTeX
@article{Peters2024,
author = {Peters, Tessa M A and Engelke, Udo F H and de Boer, Siebolt and Reintjes, Joris T G and Roullet, Jean-Baptiste and Broekman, Sanne and de Vrieze, Erik and van Wijk, Erwin and Wamelink, Mirjam M C and Artuch, Rafael and Barić, Ivo and Merx, Jona and Boltje, Thomas J and Martens, Jonathan and Willemsen, Michèl A A P and Verbeek, Marcel M and Wevers, Ron A and Gibson, K Michael and Coene, Karlien L M},
title = {Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective},
journal = {Journal of Inherited Metabolic Disease},
year = {2024},
doi = {10.1002/jimd.12657}
}
EUVIMED